Seeking Alpha

Allergan BOD rejects latest Valeant offer

  • Unsurprisingly, Allergan's (AGN) BOD rejects Valeant Pharmaceuticals' (VRX) latest offer of 0.83 shares of Valeant common stock plus $72 in cash for each share of AGN common stating that its offer substantially undervalues Allergan. It also cites the large component of VRX stock in the proposal. The Board believes its value is uncertain due to its perception of the lack of sustainability of VRX's business model.
  • Pershing Square believes it has the shareholder votes to override the Board's decision and accept the proposal.
Comments (1)
  • thodoris91
    , contributor
    Comments (52) | Send Message
    good for them
    10 Jun, 01:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: